Ⅳ期非小细胞肺癌联合化疗的分析  

Clinical effects of combined chemotherapy in patients with stage Ⅳ nonsmall cell lung cancer

作　　者：许宾[1] 康彬[1] 肖林之[1] 陈峥妍[1] 付晨[2] 

机构地区：[1]复旦大学附属上海市第五人民医院(筹)老年科,上海200240 [2]上海市卫生局政策研究室

出　　处：《肿瘤》2002年第2期139-141,共3页Tumor

摘　　要：目的　联合化学治疗Ⅳ期非小细胞肺癌 (NSCLC) 6 9例的疗效分析。方法　选择 6 9例NSCLCⅣ期初治患者 ,其中 35例接受顺铂 (DDP) 2 0mg/m2 第 1～ 5天 ;长春花碱酰胺 (VDS) 3mg/m2 第 1,8天 ;依托泊苷 (VP - 16 ) 10 0mg/m2 第 1～ 3天 ,2 1～ 2 8天为 1周期 ,至少 4个周期。 34例拒绝化疗者仅给予支持疗法。结果　中位生存期化疗组为 11.6月 ,对照组为 3.8月。 1年生存率化疗组为 4 5 .7% ,对照组为 0。治疗后Karnofsky评分化疗组明显优于对照组。化疗毒副作用主要表现为 ,胃肠道反应 94 .3% ,白细胞下降 91.4 % ,脱发 4 5 .7%。结论　联合化疗可延长Ⅳ期NSCLC生存期 ,改善生活质量。Objective To study the clinical effects of combined chemotherapy with cisplatin in the treatment of advanced non small cell lung cancer (NSCLC). Methods Previously untreated staged Ⅳ NSCLC were included in this study. As the chemotherapy group, 35 patients received cisplatin (DDP) given on day 1～5 with a dose of 20mg/m 2 , vindesine (VDS) on day 1 and 8 with a dose of 3 mg/ m 2 and etoposide (VP-16) with a dose of 100mg/ m 2 on day 1～3. The patients in chemotherapy group were treated every 21～28 days for at least 4 cycles. 34 patients refused chemotherapy and receipted nutrition, analgesia and heteropathy. Results The median survival period was 11.6 months in chemotherapy group, and 3.8 months in control group. The 1 year survival rate in chemotherapy group was 45.7%, and was 0% in control group. Karnofsky score in study group was significanty higher than that in control group. The main toxicities were gastrointestinal reaction, leukopenia and alopecia, the incidence was 94.3%,91.45% and 45.7% respectively. Conclusion Combined chemotherapy may play a role in improving living quality and in prolonging survival period in patients with stage Ⅳ NSCLC.

关 键 词：Ⅳ期非小细胞肺癌 药物疗法 联合化疗 治疗 疗效分析 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]